- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
Complaint about use of ‘unique’ in a Trajenta (linagliptin) HCP digital banner claim. Panel ruled no breach of Clause 14.4, accepting the…
Complaint alleged a Lixiana initiation “webinar” omitted hepatic monitoring/contraindications and included a dosing interaction error. Panel found no breach as content was…
PMCPA found Novartis breached the ABPI Code over an Entresto nurse podcast: an unsubstantiated ‘energy’ claim, ‘best’ implying superiority, and unqualified renal…
Small Pharma’s open-access website discussed psychedelic pipeline programmes using strong, unqualified language without clearly identifying the intended audience. PMCPA ruled a breach…
Anonymous complaint alleged a Guardian-sponsored SOBI corporate article was disguised promotion and misleading. PMCPA Panel ruled no breach of Clauses 3.6, 5.1,…
PMCPA found Novartis’ Jakavi HCP webpage claim “Improved survival benefit compared with BAT” misleading and unsubstantiated because it implied statistically significant survival…
Complaint alleged Rinvoq dosing web copy implied it could be taken with any food (incl. grapefruit) despite SPC advice to avoid grapefruit.…
GSK’s HCP webpage/video used an NMA to headline “greater exacerbation reduction” vs other COPD SITTs. PMCPA ruled the headline comparison misleading (Clauses…
A health professional alleged a Lilly representative repeatedly visited a dermatology department without prior authorisation and dropped off items/samples. The Panel found…
Two sponsored cardiovascular disease articles on a charity website disclosed Daiichi Sankyo’s involvement only at the bottom of long pages. PMCPA found…
Grünenthal admitted a market access employee calling on HCPs did not take the ABPI exam modules within the first year of employment.…
Three UK AstraZeneca employees ‘liked’ a third‑party LinkedIn post about pre-clinical osimertinib resistance reversal. PMCPA said the likes disseminated favourable content to…
PMCPA found GSK’s Tackle Meningitis site showed substantive desktop vs mobile differences on two pages. Each final form should have been certified…
Complaint alleged Daiichi Sankyo’s sponsorship of an event wasn’t clear on the website home/registration pages. Panel found sponsorship disclosure and sponsor list…
PMCPA ruled an AstraZeneca LinkedIn post was promotional for Calquence (CLL) and lacked mandatory digital prescribing/safety information (PI, INN, AE statement, black…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.